Spire Wealth Management Biomarin Pharmaceutical Inc Transaction History

Spire Wealth Management

$2.95 Billion
Q3 2024

A detailed history of Spire Wealth Management transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Spire Wealth Management holds 153 shares of BMRN stock, worth $10,194. This represents 0.0% of its overall portfolio holdings.

Number of Shares

153

Previous 160 4.38%

Holding current value

$10,194

Previous $13,000 23.08%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 15, 2024	SELL	$69.02 - $93.84 $483 - $656	-7 Reduced 4.38%	153 $10,000
Q2 2024 Jul 31, 2024	BUY	$74.43 - $92.22 $5,731 - $7,100	77 Added 92.77%	160 $13,000
Q1 2024 Apr 24, 2024	SELL	$83.81 - $99.0 $251 - $297	-3 Reduced 3.49%	83 $7,000
Q3 2023 Nov 08, 2023	BUY	$85.07 - $94.48 $935 - $1,039	11 Added 14.67%	86 $7,000
Q2 2023 Aug 09, 2023	SELL	$86.68 - $100.3 $2.28 Million - $2.64 Million	-26,289 Reduced 99.72%	75 $6,000
Q1 2023 May 09, 2023	BUY	$87.74 - $117.27 $2.3 Million - $3.08 Million	26,236 Added 20496.88%	26,364 $2.56 Million
Q2 2022 Jul 22, 2022	SELL	$71.48 - $86.85 $5,361 - $6,513	-75 Reduced 36.95%	128 $11,000
Q1 2022 Apr 18, 2022	SELL	$74.28 - $92.69 $12,924 - $16,128	-174 Reduced 46.15%	203 $16,000
Q4 2021 Jan 14, 2022	BUY	$71.72 - $91.47 $10,112 - $12,897	141 Added 59.75%	377 $33,000
Q3 2021 Oct 22, 2021	BUY	$74.77 - $85.47 $2,691 - $3,076	36 Added 18.0%	236 $18,000
Q2 2021 Jul 26, 2021	SELL	$75.51 - $84.79 $29,373 - $32,983	-389 Reduced 66.04%	200 $17,000
Q1 2021 May 21, 2021	BUY	$74.73 - $90.69 $44,015 - $53,416	589 New	589 $44,000

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Spire Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Spire Wealth Management with notifications on news.

Account

Spire Wealth Management Biomarin Pharmaceutical Inc Transaction History